Post-Market NASDAQ Movers (CXDC, BEAT, ALTH, CLDX, CISG, OMER, ASTI, LOGI, EXFO, XRTX)

The top after-market NASDAQ Stock Market gainers are: China XD Plastics Company, CardioNet, Allos Therapeutics, Celldex Therapeutics, and Cninsure. The top after-market NASDAQ Stock Market losers are: Omeros, Ascent Solar Technologies, Logitech International, EXFO, and Xyratex.

Gainers

China XD Plastics Company Ltd. (CXDC) stock jumped 11.32 percent to $5.80 in the after-market trading. Profit for the fourth quarter was $6.5 million, compared to a loss of $6.0 million last year. Earnings per share were 14 cents a share. Adjusted profit was $17.2 million or 36 cents a share. Revenue grew 75.6 percent to $72.4 million. Analysts had expected profit of 23 cents a share on revenue of $64.50 million. For the fiscal 2011, the company expects adjusted earnings of $48 million to $51 million and revenue of $280 million to $310 million, while Street predicts revenue of $314.18 million.

CardioNet, Inc. (BEAT) stock grew 6.47 percent to $5.10 in the after-market trading.

Allos Therapeutics, Inc. (ALTH) stock gained 5.70 percent to $3.34 in the after-market trading.

Celldex Therapeutics, Inc. (CLDX) stock increased 4.98 percent to $4.22 in the after-market trading.

Cninsure Inc. (CISG) stock rose 4.78 percent to $13.58 in the after-market trading.

Losers

Omeros Corp. (OMER) stock plunged 38.13 percent to $4.95 in the after-market trading, as its drug to reduce pain after arthroscopic knee surgeries failed to meet endpoints in phase 3 program. The company said its Phase 3 program evaluating OMS103HP failed to meet to the pre-specified endpoints of these studies. OMS103HP is indicated for the patients undergoing arthroscopic anterior cruciate ligament (ACL) reconstruction surgery. No conclusions could be made regarding drug effect due to confounding factors in the studies, the company added.

Our analysis of the data does not demonstrate a lack of drug effect nor does it appear to undermine the viability of our Phase 3-ready OMS103HP program for meniscectomy surgery. As we learn more from our data analysis, we will provide additional information on our plans for OMS103HP. In the meantime, we are continuing to advance our pipeline, including our ophthalmology program, for which we recently announced positive Phase 2b data, and our successful GPCR program. said Gregory Demopulos, chief executive officer of Omeros.

Ascent Solar Technologies, Inc. (ASTI) stock plummeted 12.54 percent to $2.51 in the after-market trading. The company announced a change in strategy that will focus the company’s groundbreaking lightweight, flexible thin-film solar module technology on applications for emerging and specialty markets. The new market focus provides a clear path for the future and leverages the company’s unique strengths. The change in strategy will mean a change in leadership and sizing the company to a new cost structure.

Ascent said producing solar modules that are exceptionally lightweight and flexible gives Ascent the ability to meet specialty needs for markets like the military and defense; custom near-space applications; off-grid charging solutions in developing countries; power for portable electronics; and custom and standard products for rooftop integration on buses, trucks and trains. Ascent believes that it can sell its products in these markets at more attractive margins than currently possible for ground mount applications or BIPV and BAPV markets.

With the change in strategy, chief executive officer Farhad Moghadam is stepping down to pursue other interests and opportunities. Ron Eller, an Ascent board member for the past two years, has been appointed the company’s new president and chief executive officer.

Logitech International SA (LOGI) stock fell 9.87 percent to $16.34 in the after-market trading, as it cut fiscal 2011 guidance due to weakness in its Europe, Middle-East and Africa retail sales region. The company lowered 2011 sales outlook to range of $2.35 billion to $2.37 billion from previous range of $2.40 billion to $2.42 billion, while Street predicts $2.41 billion. The company also reduced its fiscal 2011 operating earnings guidance to range of $140 million to $150 million from previous forecast of $170 million to $180 million.

EXFO Inc. (EXFO) stock tumbled 8.23 percent to $10.03 in the after-market trading, as it guided third quarter below Street view. The company expects third quarter earnings of 1 cent to 5 cents a share and sales of $67 million to $72 million, while Street predicts profit of 11 cents a share on revenue of $73.17 million.

EXFO reported second quarter earnings of $1.7 million or 3 cents a share, up from $1.2 million or 2 cents a share last year. The latest quarter results included $2.4 million in amortization of intangible assets and $0.6 million in stock-based compensation costs. The former item resulted in an income tax recovery of $0.2 million. The company also reported a foreign exchange loss of US$2.4 million in the second quarter of 2011. Sales grew 50.2 percent to $72 million. Analysts had expected profit of 10 cents a share on revenue of $73.19 million.

Xyratex Ltd. (XRTX) stock slid 6.81 percent to $10.40 in the after-market trading, as it guided second quarter below Street view. The company expects second quarter adjusted results between loss of 12 cents a share and profit of 6 cents a share. The company anticipates revenue of $320 million to $365 million. Street analysts currently expect profit of 28 cents a share on revenue of $384.54 million.

The company posted first quarter adjusted earnings of $7.5 million or 24 cents a share, down from $29.4 million or 96 cents a share last year. Revenue rose 13 percent to $360.50 million. Analysts had expected profit of 23 cents a share on revenue of $374.86 million.

It also said its board of directors has authorized a recommencement of the share repurchase plan it initially approved during the first quarter of 2008, and to increase the maximum value of shares that may be repurchased. According to the revised terms of the plan, the company may repurchase up to an additional $50 million of its outstanding shares following April 30, 2011. As of February 28, 2011, Xyratex had 30.9 million shares outstanding.